The objective of this supplement proposal is to understand the causes of airway diseases and thereby improve diagnosis and therapy of these common and debilitating of human ailments. The Immunophenotyping Assessment in a COVID-19 Cohort (IMPACC) study coordinates a national, multi-institution consortium, collecting detailed clinical data and biologic samples from hospitalized COVID-19 infected individuals, with the goal of identifying immune signatures/molecular biomarkers associated with clinical disease course, to allow the prioritization of clinical interventions and decision making. This supplement supports Baylor College of Medicine's and the Michael E. DeBakey VA Medical Center's (MEDVAMC) participation in IMPACC to facilitate screening and enrollment of inpatients with COVID-19. The proposed supplement research is within the scope of parent grant R01 AI135803, Fungal Pathogenesis of Moderate to Severe Asthma. This supplement is submitted for the purpose of Clinical data and sample collection/processing and the scope will be confined to patients confirmed to have COVID-19. Based on projected trends in COVID-19 disease in MEDVAMC, we estimate that up to 50 COVID-19 patients can be enrolled within 6 months. As enrollees will be followed for up to one year, the budget extends to 18 months. Data to be collected will consist of both primary and secondary clinical and mechanistic endpoints as well as exploratory clinical and mechanistic endpoints.
The objective of this supplement proposal is to partner with the National Institutes of Health on a larger study of patients with severe coronavirus disease (COVID-19). The findings from this study will provide a better understanding of COVID-19 and eventually lead to improved ways to diagnose and treat this new viral infection.
